erlotinib hydrochloride has been researched along with Pachyonychia Congenita in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basset, J; Hovnanian, A; Marchal, L | 1 |
1 other study(ies) available for erlotinib hydrochloride and Pachyonychia Congenita
| Article | Year |
|---|---|
EGFR Signaling Is Overactive in Pachyonychia Congenita: Effective Treatment with Oral Erlotinib.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Humans; Keratoderma, Palmoplantar; Mutation; Pachyonychia Congenita; Pain; Quality of Life | 2023 |